Prevalence of the metabolic syndrome and its components: Findings from a Finnish general population sample and the Diabetes Prevention Study cohort

Diabetes Care

Volumn 27, Issue 9, 2004, Pages 2135-2140

  Ilanne Parikka, Pirjo ^a,b   Eriksson, Johan G ^c   Lindström, Jaana ^c   Hämäläinen, Helena ^d   Keinänen Kiukaanniemi, Sirkka ^e,f   Laakso, Mauri ^e,f   Louheranta, Anne ^g   Mannelin, Marjo ^f   Rastas, Merja ^c   Salminen, Virpi ^c   Aunola, Sirkka ^c   Sundvall, Jouko ^c   Valle, Timo ^c   Lahtela, Jorma ^b   Uusitupa, Matti ^g   Tuomilehto, Jaakko ^c  

^a Finnish Diabetes Association   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d SOCIAL INSURANCE INSTITUTION   (Finland)

^e UNIVERSITY OF OULU   (Finland)

^f OULU UNIVERSITY HOSPITAL   (Finland)

^g UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; ANTHROPOMETRY; ARTICLE; ATHEROSCLEROSIS; COHORT ANALYSIS; DETERIORATION; FEMALE; FINLAND; GLUCOSE METABOLISM; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION RESEARCH; PREVALENCE; PREVENTIVE MEDICINE; RISK FACTOR; VASCULAR DISEASE; WORLD HEALTH ORGANIZATION;

BODY MASS INDEX; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FINLAND; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE;

EID: 4444278225     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.27.9.2135     Document Type: Article

References (33)

1. Amos AF, McCarty DJ, Zimmet P: The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 14:S1-S85, 1997
2. King H, Aubert RE, Herman WH: Global burden of diabetes, 1999-2025: prevalence, numerical estimates, and projections. Diabetes Care 20:1414-1431, 1998
3. Uusitupa M: Lifestyles matter in the prevention of type 2 diabetes. Diabetes Care 25:1650-1651, 2002
4. The DECODE Study Group: Glucose tolerance and mortality: comparison of WHO and American Diabetes Association Diagnostic Criteria. Lancet 354:617-621, 1999
5. King H, Dowd JE: Primary prevention of type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 33:3-8, 1990
6. Tuomilehto J, Tuomilehto-Wolf E, Zimmet P, Alberti K, Knowler W: Primary prevention of diabetes mellitus. In International Textbook of Diabetes Mellitus. Alberti K, Zimmet P, DeFronzo R, Keen H, Eds. New York, Wiley, 1997, p. 1799-1827
7. Hamman RF: Genetic and environmental determinants of non-insulin- dependent diabetes mellitus (NIDDM). Diabetes Metab Rev 8:287-338, 1992
8. Reaven GM: Role of insulin resistance in human disease. Diabetes 37:1595-607, 1998
9. World Health Organization: Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Partl. Diagnosis and Classification of Diabetes Mellitus. Geneva, World Health Org., 1999 (Tech. Rep. Ser., no. 99.2)
10. Balkau B, Charles MA: Comment on the provisional report from the WHO consultation: European Group for the Study of Insulin Resistance (EGIR). Diabet Med 16: 442-443, 1999
11. National Institutes of Health: Third Report on the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Washington, DC, U.S. Govt. Printing Office, 2001 (NIH publ. no. 01-3670)
12. Bloomgarden ZT: Perspectives in Diabetes: American Association of Clinical Endocrinologists (AACE) Consensus Conference on the Insulin Resistance Syndrome, 25-26 August 2002, Washington, D.C. Diabetes Care 26:933-939, 2003
13. Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, Taskinen M-R, Groop L: Cardiovascular morbidity and mortality associated with the MetS. Diabetes Care 24:683-689, 2001
14. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stem MP: Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 41: 715-722, 1992
15. Mykkänen L, Kuusisto J, Pyörälä K, Laakso M: Cardiovascular disease risk factors as predictors on type 2 (non-insulin- dependent) diabetes mellitus in elderly subjects. Diabetologia 36:553-559, 1993
16. Lorenzo C, Okoloise M, Williams K, Stem MP, Haffner SM: The MetS as predictor of type 2 diabetes. Diabetes Care 26:3153-3159, 2003
17. Trevisan M, Liu J, Bahsas F, Menotti A: Syndrome X and mortality: a population-based study: Risk Factor and Life Expectancy Research Group. Am J Epidemiol 148: 958-966, 1998
18. Lakka HM, Laaksonen D, Lakka T, Niskanen L, Kumpusalo E, Tuomilehto J, Salonen J: The MetS and total and cardiovascular disease mortality in middle-aged men. JAMA 228:2709-2716, 2002
19. Isomaa B, Henricsson M, Almgren P, Tuomi T, Taskinen M-R, Groop L: The MetS influences the risk of chronic complications in patients with type II diabetes. Diabetologia 44:1148-1154, 2001
20. Lehto S, Rönnemaa T, Pyörälä K, Laakso M: Cardiovascular risk factors clustering with endogenous hyperinsulinemia predict death from coronary heart disease in patients with type II diabetes. Diabetologia 43:148-155, 2000
21. World Health Organization: WHO Monica Project: MONICA manual [article online]. Available from http/www.ktl.fi/ publications/monica/manual. Accessed 10 October 2003
22. Tuomilehto J, Arstila M, Kaarsalo E, Kankaanpää J, Ketonen M, Kuulasmaa K, Lehto S, Miettinen H, Mustaniemi H, Palomäki P, Puska P, Pyörälä K, Salomaa V, Torppa J, Vuorenmaa T: Acute myocardial infarction (AM1) in Finland: baseline data from the FINMONICA AM1 register in 1983-1985. Eur Heart J 13:577-587, 1992
23. Vartiainen E, Puska P, Pekkanen J, Tuomilehto J, Jousilahti P: Changes in risk factors explain changes in mortality from ischaemic heart disease in Finland. Br Med J 309:23-27, 1994
24. World Health Organization: Diabetes Mellitus: Report of a WHO Study Group. Geneva, World Health Org., 1985 (Tech. Rep. Ser., no. 727)
25. Uusitupa M, Louheranta A, Lindström J, Valle T, Sundvall J, Eriksson J, Tuomilehto J, on behalf of the Finnish Diabetes Prevention Study Group: The Finnish Diabetes Prevention Study. Br J Nutr 83 (Suppl. 1):S137-S142, 2000
26. Tuomilehto J, Lindström J, Eriksson J, Valle T, Hämä läinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M, the Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350, 2001
27. Eriksson J, Lindstrom J, Valle T, Aunola S, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Lauhkonen M, Lehto P, Lehtonen A, Louheranta A, Mannelin M, Martikkala V, Rastas M, Sundvall J, Turpeinen A, Viljanen T, Uusitupa M, Tuomilehto J: Prevention of type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland: study design and 1-year interim report on the feasibility of the lifestyle intervention programme. Diabetologia 42:793-801, 1999
28. DeFronzo RA, Ferrannini E: Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 3:173-194, 1991
29. Balkau BJ, Vernay M, Mhamdi L, Novak M, Arondel D, Vol S: D.E.S.I.R. Study Group: The frequency and incidence of the NCEP (National Cholesterol Education Program) MetS in the French D.E.S.I.R. study (Abstract). Diabetologia 45: A15, 2002
30. Laaksonen DE, Lakka H-M, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA: Metabolic syndorme and development of diabetes mellitus: application and validation of recently suggested definitions of the MetS in a prospective cohort study. Am J Epidemiol 156:1070-1077, 2002
31. Balkau B, Charles MA, DrivsholmT, Borc-Johansen K, Wareham N, Yudkin JS, Morris R, Zavaroni I, van Dam R, Feskins E, Gabriel R, Diet M, Nilsson P, Hedblad B, European Group for the Study of Insulin Resistance (EGIR): Frequency of the WHO MetS in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 28:364-376, 2002
32. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targhe G, Alberiche M, Bonadonna RC, Muggeo M: Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 47:1643-1649, 1998
33. Knowler WC, Barrett-Connor E, Fowlwe SE, Hamman RF, Lachin JM, Walker EA, Nathan DM: Reduction in the inscidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002